Skip to main content
Clinical Trials/NCT06760377
NCT06760377Not yet recruitingNot Applicable

Dietary Supplements for Reduction of Intestinal Permeability Levels

Universidad Complutense de Madrid1 site in 1 country85 target enrollmentStarted: February 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
85
Locations
1
Primary Endpoint
Zonulin levels in feces

Study Overview

Brief Summary

A randomised and controlled trial, in which the effect of a dietary supplement is evaluated for reduction of intestinal permeability levels of subjects with high levels of zonulin in feces

Detailed Description

Randomized clinical trial, with masking of the statistician and the evaluator, to assess the effect of a food supplement, composed of substances that promote intestinal mucosa repair, on the levels of zonulin in feces and consequently on intestinal permeability. A control group of subjects not receiving any type of supplementation will be used to compare the effectiveness of the treatment.

The main objective of this study is to determine if the use of a dietary supplement composed of glutamine, butyrate and lion's mane, among others, corrects the levels of zonulin in feces.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Subjects between 18 and 65 years of age with elevated levels of zonulin in stool (greater than 80 ng/ml).

Exclusion Criteria

  • •Taking any type of antibiotic in the last month
  • •Taking prebiotics or probiotics products in the last month.
  • •Taking laxatives in the last month.
  • •Undergoing any medicinal treatment
  • •Pregnancy
  • •Subject with a history of current gastrointestinal pathology or disorder such as: acute colon pathology, acute haemorrhagic colitis, suspected digestive perforation, recent abdominal surgery, severe arterial hypertension, abdominal hernia, colon neoplasia, history of cardiac syncope, renal failure, liver cirrhosis, epilepsy, severe psychiatric illness (psychosis), necrosis due to abdominal irradiation, severe anaemia, severe neurovegetative lability.

Arms & Interventions

Dietary supplement Group

Experimental

Subjects belonging to the experimental group will be provided with the PermeaIntest supplement, which they will take for 60 days, 1 sachet in the morning and 1 sachet in the evening in half a glass of water. Subjects will have a stool sample collected before and after ingestion of the dietary supplement.

Intervention: Dietary supplement Group (Dietary Supplement)

Control group

No Intervention

A control group of subjects not receiving any type of supplementation will be used to compare the effectiveness of the treatment. Subjects will have a stool sample collected before and after a period of 60 days

Outcomes

Primary Outcomes

Zonulin levels in feces

Time Frame: 60 days

Zonulin levels in feces, assessed in ng/ml

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Isidro Fernández López

Principal investigator

Universidad Complutense de Madrid

Study Sites (1)

Loading locations...

Similar Trials